{"gene":"PRKCE","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2017,"finding":"A de novo partial loss-of-function mutation in PRKCE (PKCε) causes SHORT syndrome by impairing mTORC2-dependent AKT activation. The mutant PKCε bound to the mTORC2 component SIN1 with higher affinity than wild-type, altered mTORC2-dependent priming dynamics, and caused impaired mTORC2-dependent pAKT-S473 following rapamycin treatment, as well as reduced pFOXO1-S256 and pS6-S240/244 in patient lymphoblasts. Interaction with PDK1 and SIN1 was preserved in the mutant.","method":"Whole exome sequencing, kinase activity assay, phospho-specific antibody immunoblotting in patient lymphoblasts and HEK293 ectopic expression, co-immunoprecipitation of PDK1/SIN1 interactions","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction studies, kinase assay, phospho-readouts with multiple substrates, patient + cell-line models in a single focused study","pmids":["28934384"],"is_preprint":false},{"year":2017,"finding":"PRKCE is a direct target of miR-218-5p: miR-218-5p overexpression repressed luciferase activity of reporter constructs containing the 3'-UTR of PRKCE and reduced PRKCE protein expression. PRKCE promotes gemcitabine resistance in gallbladder cancer cells through upregulation of MDR1/P-glycoprotein.","method":"Luciferase 3'-UTR reporter assay, miRNA overexpression/knockdown, Western blotting, cell viability assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'-UTR reporter assay plus functional rescue experiments in cells, single lab","pmids":["28492560"],"is_preprint":false},{"year":2013,"finding":"miR-146a directly binds the 3'-UTR of PRKCE (confirmed by luciferase reporter assay) and decreases PKCε protein levels in papillary thyroid carcinoma cells, leading to increased apoptosis and suppressed tumor growth in a subcutaneous xenograft model. PKCε acts downstream of the Ras/Raf-1 pathway and inhibits mitochondrial apoptosis in thyroid cancer cells.","method":"Luciferase 3'-UTR reporter assay, miR-146a stable overexpression, Western blotting, apoptosis assays, xenograft tumor growth","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'-UTR reporter plus in vivo rescue, single lab","pmids":["23457043"],"is_preprint":false},{"year":2020,"finding":"miR-205-5p directly targets PRKCE (validated by luciferase reporter assay) and negatively regulates its expression in gallbladder cancer stem cells. Overexpression of miR-205-5p or silencing of PRKCE inhibited drug resistance, proliferation, and colony formation while promoting apoptosis, and attenuated gemcitabine resistance in vivo.","method":"Luciferase 3'-UTR reporter assay, miRNA overexpression, PRKCE knockdown, apoptosis assays (Bax, Bcl-2, cleaved caspase 3 Western blot), mouse xenograft model","journal":"Bioscience reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'-UTR reporter plus in vivo xenograft, single lab","pmids":["32869841"],"is_preprint":false},{"year":2011,"finding":"Deletion of Prkce in mice protects against diet-induced glucose intolerance via two temporally distinct mechanisms: (1) early protection via altered hepatic lipid partitioning that reduces fatty acid catabolism-derived reactive oxygen species (ROS), and (2) later enhancement of glucose-stimulated insulin secretion. Prkce-/- hepatocytes showed reduced ROS production in the presence of palmitate and altered mitochondrial oxidative capacity.","method":"Prkce knockout mice on high-fat diet, glucose tolerance tests, indirect calorimetry, iTRAQ quantitative proteomics, immunoblotting, primary hepatocyte assays, mitochondrial oxidative capacity measurements","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout model with multiple orthogonal phenotypic readouts (metabolic, proteomic, cellular) across time points","pmids":["21347625"],"is_preprint":false},{"year":2008,"finding":"Fetal cocaine exposure programs cardiac Prkce gene repression in adult male rat offspring via DNA methylation of two Sp1 binding sites (-346 and -268) in the Prkce promoter. Methylation of these sites decreased SP1 binding affinity to the promoter, and reporter gene assays confirmed both Sp1 sites have a strong stimulatory role in Prkce gene activity. The effect was sex-dependent (males but not females showed decreased Prkce mRNA and both Sp1 sites methylated).","method":"Bisulfite sequencing/methylation analysis of Prkce promoter CpGs, luciferase reporter gene assay, electrophoretic mobility shift/SP1 binding assays, RT-PCR, in vivo rat model","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (methylation mapping, reporter assay, binding assay) in a single focused mechanistic study","pmids":["18945988"],"is_preprint":false},{"year":2022,"finding":"Maternal Prkce transcript in mature oocytes is critical for the first cleavage and facilitating the maternal-to-zygotic transition in mice. Prkce knockout mice showed a significantly reduced 2-cell rate (32.4% vs 80.1% in wild-type) that was rescued by Prkce cRNA injection (76.7% 2-cell rate). Global transcriptional analysis of knockout embryos revealed 143 differentially expressed genes largely enriched in cell cycle regulation pathways.","method":"Prkce knockout mice, in vitro fertilization, cRNA rescue injection, microarray/RNA sequencing, RT-qPCR, Western blotting, immunofluorescence","journal":"Cell proliferation","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with rescue experiment, multiple orthogonal methods in a single focused study","pmids":["35582855"],"is_preprint":false},{"year":2015,"finding":"IPS-1-mediated anticancer signaling via IRF3 and IRF7 downregulates PRKCE (along with BCL2 and BIRC3) as part of its anti-apoptotic gene suppression program. Stable knockdown of IPS-1, IRF3, or IRF7 in IFN-non-responsive cancer cells reduced anticancer activity and suppressed downregulation of PRKCE.","method":"IPS-1 ectopic expression, stable shRNA knockdown of IPS-1/IRF3/IRF7, gene expression analysis, apoptosis assays in cancer cell lines","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via knockdown of pathway components with transcriptional and apoptotic readouts, single lab","pmids":["25950488"],"is_preprint":false},{"year":2025,"finding":"PKCε deficiency in the central nervous system leads to cerebral and cerebellar atrophy and motor/social deficits. Mechanistically, deletion of PKCε results in downregulation of VEGF/PI3K-induced AKT activation, causing abnormal brain development. This is consistent with the SHORT syndrome phenotype previously linked to PRKCE mutation.","method":"Prkce knockout mice (CNS-specific), brain morphometry, behavioral testing, phospho-specific immunoblotting of AKT pathway components","journal":"Neuroscience bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean knockout with pathway readout, single lab, single paper","pmids":["40914752"],"is_preprint":false},{"year":2025,"finding":"A PRKCE::ETV6 fusion gene resulting from a complex chromosomal rearrangement of chromosomes 2 and 12 in near-ETP T-ALL confers interleukin-independent proliferation and enhanced survival in cytokine-dependent cellular models (Ba/F3 pro-B cells and D1 T-cells), supporting its role as an oncogenic driver.","method":"Targeted genomic capture high-throughput sequencing, RNA sequencing, RT-PCR, Sanger sequencing, FISH, ectopic expression of PRKCE::ETV6 fusion in Ba/F3 and D1 cell lines, IL-independent proliferation and survival assays","journal":"Molecular and cellular pediatrics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell-based assay with two independent cell line models demonstrating transforming potential, single lab","pmids":["41123786"],"is_preprint":false},{"year":2025,"finding":"In bladder cancer cells, decreased PRKCE expression (associated with the rs4953292 A allele combined with 4-aminobiphenyl treatment) upregulates PKG and promotes phosphorylation of VASP within the cGMP-PKG signaling pathway, enhancing glucose uptake, lactate generation, and extracellular acidification rate to reprogram glycolysis, thereby promoting bladder cancer susceptibility.","method":"Functional experiments in 4-ABP-treated bladder cancer cells, allele-specific PRKCE expression analysis, ECAR measurement, lactate/glucose uptake assays, phospho-VASP immunoblotting","journal":"Environment & health","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional cell-based mechanistic assays with pathway readouts, single lab, single paper","pmids":["41883368"],"is_preprint":false},{"year":2024,"finding":"PRKCE protein associates with ribosomal complexes specifically in subcerebral projection neurons (SCPN) but not callosal projection neurons (CPN) during axonal connectivity establishment in mouse cortex. This SCPN-specific ribosome association was validated by ribosome immunoprecipitation and PKCε has enriched gene expression in SCPN, suggesting a role in subtype-specific translational regulation during circuit formation.","method":"Retrograde neuronal labeling, FACS purification of neuron subtypes, ribosome immunoprecipitation, ultra-low-input mass spectrometry, gene expression analysis","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ribosome pulldown in sorted neurons, preprint, single lab, functional consequence not yet experimentally established","pmids":[],"is_preprint":true},{"year":2024,"finding":"Myeloid PKCε restricts lipid uptake in macrophages by a mechanism independent of scavenger receptor expression. PKCε-deficient macrophages (mεKO) retained significantly more cholesterol and lipid droplets upon lipid loading in vitro and in vivo, and RNA sequencing implicated higher expression of genes related to endocytosis in mεKO macrophages. mεKO mice developed larger atherosclerotic plaques with more necrosis and thinner collagen caps.","method":"Myeloid-specific Prkce knockout mice (LysM Cre PKCε fl/fl), bone marrow-derived macrophage lipid loading assays, cholesterol retention assays, RNA sequencing, in vivo hypercholesterolemia model, plaque histomorphometry","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean conditional knockout with in vitro and in vivo phenotypic readouts and RNA sequencing pathway analysis, preprint","pmids":[],"is_preprint":true}],"current_model":"PKCε (PRKCE) is a serine/threonine kinase that operates at the intersection of multiple signaling pathways: it facilitates mTORC2-dependent AKT activation (loss-of-function mutations cause SHORT syndrome), promotes MDR1/P-gp-mediated drug resistance in cancer, modulates hepatic lipid partitioning and mitochondrial ROS production to influence glucose homeostasis, drives Prkce promoter activity via Sp1 binding sites (subject to epigenetic repression by DNA methylation), is required for the first embryonic cleavage by supporting cell cycle regulation during maternal-to-zygotic transition, restricts macrophage lipid uptake independently of scavenger receptor expression, and regulates glycolytic reprogramming through the cGMP-PKG pathway; its activity is spatiotemporally controlled by subcellular targeting to sarcomeres, mitochondria, and ribosomal complexes in a cell-type-specific manner."},"narrative":{"mechanistic_narrative":"PRKCE encodes PKCε, a serine/threonine kinase that integrates growth-factor, metabolic, and stress signaling to regulate cell survival, lipid handling, and development [PMID:28934384, PMID:21347625]. In the mTORC2 module, PKCε engages the mTORC2 component SIN1 to support mTORC2-dependent priming and AKT-S473 phosphorylation; a de novo partial loss-of-function mutation that binds SIN1 with higher affinity and impairs downstream pAKT-S473, pFOXO1-S256, and pS6 phosphorylation causes SHORT syndrome [PMID:28934384], and CNS-restricted loss likewise downregulates VEGF/PI3K-driven AKT activation, producing cerebral and cerebellar atrophy with motor and social deficits [PMID:40914752]. Metabolically, PKCε shapes hepatic lipid partitioning and mitochondrial oxidative capacity, with its deletion reducing fatty-acid-derived ROS and protecting against diet-induced glucose intolerance [PMID:21347625], and in macrophages it restricts cholesterol and lipid-droplet accumulation independently of scavenger-receptor expression, limiting atherosclerotic plaque burden. In cancer, PKCε is anti-apoptotic: it acts downstream of Ras/Raf-1 to inhibit mitochondrial apoptosis [PMID:23457043] and drives MDR1/P-glycoprotein-mediated gemcitabine resistance [PMID:28492560], and it is held in check by multiple microRNAs (miR-218-5p, miR-146a, miR-205-5p) that bind its 3'-UTR [PMID:28492560, PMID:23457043, PMID:32869841]. PKCε is also required for the first embryonic cleavage and the maternal-to-zygotic transition through cell-cycle gene regulation [PMID:35582855], and its own promoter is controlled by Sp1-binding sites subject to DNA-methylation-dependent repression [PMID:18945988].","teleology":[{"year":2008,"claim":"Established how PRKCE expression itself is transcriptionally controlled, showing the gene is a methylation-sensitive Sp1 target and a node for epigenetic programming.","evidence":"Bisulfite methylation mapping, luciferase reporter and SP1 binding assays in a fetal-cocaine-exposure rat model","pmids":["18945988"],"confidence":"High","gaps":["Sex-specific basis of the methylation effect not mechanistically explained","Does not address PKCε protein function, only its transcriptional regulation"]},{"year":2011,"claim":"Defined a metabolic role for PKCε, resolving that its deletion protects against glucose intolerance via hepatic lipid partitioning/ROS and enhanced insulin secretion.","evidence":"Prkce knockout mice on high-fat diet with glucose tolerance tests, proteomics, and primary hepatocyte mitochondrial assays","pmids":["21347625"],"confidence":"High","gaps":["Direct kinase substrates linking PKCε to lipid partitioning not identified","Tissue source of the insulin-secretion benefit not pinpointed"]},{"year":2013,"claim":"Showed PKCε is an anti-apoptotic effector downstream of Ras/Raf-1 and a direct microRNA target, framing it as a tumor-promoting kinase.","evidence":"miR-146a 3'-UTR luciferase reporter, overexpression, apoptosis assays and xenografts in papillary thyroid carcinoma","pmids":["23457043"],"confidence":"Medium","gaps":["Direct substrates mediating mitochondrial apoptosis inhibition not defined","Single tumor type"]},{"year":2015,"claim":"Placed PRKCE within an innate-immune anti-cancer program, identifying it as a gene suppressed by IPS-1/IRF3/IRF7 signaling.","evidence":"IPS-1 expression and shRNA knockdown of IPS-1/IRF3/IRF7 with transcriptional and apoptosis readouts in cancer cells","pmids":["25950488"],"confidence":"Medium","gaps":["Whether PRKCE downregulation is causal for the apoptotic effect or correlative not resolved","Direct transcriptional control of PRKCE by IRFs not demonstrated"]},{"year":2017,"claim":"Connected PKCε to drug resistance, showing miR-218-5p represses PRKCE and that PKCε drives MDR1/P-glycoprotein-mediated gemcitabine resistance.","evidence":"3'-UTR luciferase reporter, miRNA modulation, and viability assays in gallbladder cancer cells","pmids":["28492560"],"confidence":"Medium","gaps":["Mechanism linking PKCε activity to MDR1 upregulation not defined","No in vivo resistance model in this study"]},{"year":2017,"claim":"Defined PKCε's role in the mTORC2-AKT axis and established its first Mendelian disease link, showing a SIN1-binding partial loss-of-function mutation causes SHORT syndrome.","evidence":"Whole exome sequencing, kinase assays, co-IP of PDK1/SIN1, and phospho-readouts in patient lymphoblasts and HEK293 cells","pmids":["28934384"],"confidence":"High","gaps":["Structural basis of enhanced SIN1 binding by the mutant not solved","How altered priming translates to multi-substrate AKT-pathway impairment incompletely mapped"]},{"year":2020,"claim":"Reinforced the microRNA-PKCε resistance axis in cancer stem cells, validating miR-205-5p as a further direct repressor of PRKCE.","evidence":"3'-UTR luciferase reporter, miRNA overexpression, PRKCE knockdown, and xenografts in gallbladder cancer stem cells","pmids":["32869841"],"confidence":"Medium","gaps":["Overlap/redundancy among the multiple PRKCE-targeting miRNAs not addressed","Downstream effectors of PKCε in stemness not defined"]},{"year":2022,"claim":"Revealed a developmental requirement for maternal PKCε, showing it is essential for the first embryonic cleavage and maternal-to-zygotic transition through cell-cycle gene regulation.","evidence":"Prkce knockout mice with cRNA rescue, IVF, transcriptomics, and immunofluorescence","pmids":["35582855"],"confidence":"High","gaps":["Direct kinase targets controlling the cleavage cell cycle not identified","Mechanism connecting PKCε to the 143 differentially expressed cell-cycle genes unknown"]},{"year":2025,"claim":"Extended the mTORC2/AKT role to brain development, showing CNS PKCε loss downregulates VEGF/PI3K-AKT signaling and causes atrophy, consistent with SHORT syndrome.","evidence":"CNS-specific Prkce knockout mice with morphometry, behavior, and AKT-pathway immunoblotting","pmids":["40914752"],"confidence":"Medium","gaps":["Single lab, single paper","Cell-autonomous versus vascular contribution to atrophy not separated"]},{"year":2025,"claim":"Implicated PRKCE in oncogenic gene fusion, showing a PRKCE::ETV6 fusion confers cytokine-independent proliferation in T-ALL models.","evidence":"Genomic/RNA sequencing, FISH, and ectopic fusion expression with IL-independent proliferation/survival assays in Ba/F3 and D1 cells","pmids":["41123786"],"confidence":"Medium","gaps":["Signaling output of the fusion protein not delineated","Patient-level oncogenicity beyond cell-line models not established"]},{"year":2025,"claim":"Linked reduced PRKCE to glycolytic reprogramming, showing low PKCε upregulates PKG/phospho-VASP via cGMP-PKG to enhance glycolysis and bladder cancer susceptibility.","evidence":"Allele-specific expression and functional ECAR/lactate/glucose-uptake and phospho-VASP assays in 4-ABP-treated bladder cancer cells","pmids":["41883368"],"confidence":"Medium","gaps":["Single lab, single paper","Direct mechanism by which PKCε loss derepresses PKG not defined"]},{"year":2025,"claim":"Identified a myeloid lipid-handling function, showing PKCε restricts macrophage cholesterol/lipid-droplet accumulation independently of scavenger receptors and limits atherosclerosis.","evidence":"Myeloid-specific Prkce knockout mice with macrophage lipid-loading, RNA-seq, and plaque histomorphometry (preprint)","pmids":[],"confidence":"Medium","gaps":["Endocytic genes implicated but causal substrate not identified","Preprint, not peer-reviewed"]},{"year":2024,"claim":"Suggested a subtype-specific translational role, finding PKCε associates with ribosomes selectively in subcerebral projection neurons during circuit formation.","evidence":"Ribosome immunoprecipitation and mass spectrometry in FACS-purified mouse cortical neuron subtypes (preprint)","pmids":[],"confidence":"Low","gaps":["Functional consequence of ribosome association not experimentally established","Preprint, single lab"]},{"year":null,"claim":"The direct phosphorylation substrates that mediate PKCε's effects across mTORC2 signaling, lipid metabolism, cell-cycle control, and drug resistance remain largely unidentified.","evidence":"No discovery in the corpus maps PKCε kinase activity to specific phosphorylated targets in these processes","pmids":[],"confidence":"Low","gaps":["No defined substrate set","Spatiotemporal targeting mechanisms to sarcomeres/mitochondria/ribosomes not mechanistically resolved","Unified model linking diverse phenotypes to kinase activity absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,8]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[4]},{"term_id":"GO:0005840","term_label":"ribosome","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,8,10]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4,12]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,7]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[6]}],"complexes":["mTORC2"],"partners":["SIN1","PDK1","SP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q02156","full_name":"Protein kinase C epsilon type","aliases":["nPKC-epsilon"],"length_aa":737,"mass_kda":83.7,"function":"Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis. Mediates cell adhesion to the extracellular matrix via integrin-dependent signaling, by mediating angiotensin-2-induced activation of integrin beta-1 (ITGB1) in cardiac fibroblasts. Phosphorylates MARCKS, which phosphorylates and activates PTK2/FAK, leading to the spread of cardiomyocytes. Involved in the control of the directional transport of ITGB1 in mesenchymal cells by phosphorylating vimentin (VIM), an intermediate filament (IF) protein. In epithelial cells, associates with and phosphorylates keratin-8 (KRT8), which induces targeting of desmoplakin at desmosomes and regulates cell-cell contact. Phosphorylates IQGAP1, which binds to CDC42, mediating epithelial cell-cell detachment prior to migration. In HeLa cells, contributes to hepatocyte growth factor (HGF)-induced cell migration, and in human corneal epithelial cells, plays a critical role in wound healing after activation by HGF. During cytokinesis, forms a complex with YWHAB, which is crucial for daughter cell separation, and facilitates abscission by a mechanism which may implicate the regulation of RHOA. In cardiac myocytes, regulates myofilament function and excitation coupling at the Z-lines, where it is indirectly associated with F-actin via interaction with COPB1. During endothelin-induced cardiomyocyte hypertrophy, mediates activation of PTK2/FAK, which is critical for cardiomyocyte survival and regulation of sarcomere length. Plays a role in the pathogenesis of dilated cardiomyopathy via persistent phosphorylation of troponin I (TNNI3). Involved in nerve growth factor (NFG)-induced neurite outgrowth and neuron morphological change independently of its kinase activity, by inhibition of RHOA pathway, activation of CDC42 and cytoskeletal rearrangement. May be involved in presynaptic facilitation by mediating phorbol ester-induced synaptic potentiation. Phosphorylates gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2), which reduces the response of GABA receptors to ethanol and benzodiazepines and may mediate acute tolerance to the intoxicating effects of ethanol. Upon PMA treatment, phosphorylates the capsaicin- and heat-activated cation channel TRPV1, which is required for bradykinin-induced sensitization of the heat response in nociceptive neurons. Is able to form a complex with PDLIM5 and N-type calcium channel, and may enhance channel activities and potentiates fast synaptic transmission by phosphorylating the pore-forming alpha subunit CACNA1B (CaV2.2). In prostate cancer cells, interacts with and phosphorylates STAT3, which increases DNA-binding and transcriptional activity of STAT3 and seems to be essential for prostate cancer cell invasion. Downstream of TLR4, plays an important role in the lipopolysaccharide (LPS)-induced immune response by phosphorylating and activating TICAM2/TRAM, which in turn activates the transcription factor IRF3 and subsequent cytokines production. In differentiating erythroid progenitors, is regulated by EPO and controls the protection against the TNFSF10/TRAIL-mediated apoptosis, via BCL2. May be involved in the regulation of the insulin-induced phosphorylation and activation of AKT1. Phosphorylates NLRP5/MATER and may thereby modulate AKT pathway activation in cumulus cells (PubMed:19542546). Phosphorylates and activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking (PubMed:36040231)","subcellular_location":"Cytoplasm; Cytoplasm, cytoskeleton; Cell membrane; Cytoplasm, perinuclear region; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q02156/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRKCE","classification":"Not Classified","n_dependent_lines":42,"n_total_lines":1208,"dependency_fraction":0.0347682119205298},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRKCE","total_profiled":1310},"omim":[{"mim_id":"619874","title":"CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 11; PFIC11","url":"https://www.omim.org/entry/619874"},{"mim_id":"612730","title":"SOLUTE CARRIER FAMILY 9 (SODIUM/HYDROGEN EXCHANGER), MEMBER 8; SLC9A8","url":"https://www.omim.org/entry/612730"},{"mim_id":"611546","title":"ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 6; ELOVL6","url":"https://www.omim.org/entry/611546"},{"mim_id":"611508","title":"CALMODULIN-BINDING TRANSCRIPTION ACTIVATOR 2; CAMTA2","url":"https://www.omim.org/entry/611508"},{"mim_id":"609576","title":"ACYL-CoA DEHYDROGENASE, LONG-CHAIN; ACADL","url":"https://www.omim.org/entry/609576"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Intermediate filaments","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":28.9}],"url":"https://www.proteinatlas.org/search/PRKCE"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q02156","domains":[{"cath_id":"2.60.40.150","chopping":"1-139","consensus_level":"medium","plddt":85.0564,"start":1,"end":139},{"cath_id":"3.30.60.20","chopping":"160-222_238-315","consensus_level":"medium","plddt":82.0121,"start":160,"end":315},{"cath_id":"3.30.200.20","chopping":"403-490_710-737","consensus_level":"medium","plddt":87.7797,"start":403,"end":737},{"cath_id":"1.10.510.10","chopping":"498-688","consensus_level":"medium","plddt":93.8772,"start":498,"end":688}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02156","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q02156-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q02156-F1-predicted_aligned_error_v6.png","plddt_mean":79.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRKCE","jax_strain_url":"https://www.jax.org/strain/search?query=PRKCE"},"sequence":{"accession":"Q02156","fasta_url":"https://rest.uniprot.org/uniprotkb/Q02156.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q02156/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02156"}},"corpus_meta":[{"pmid":"28492560","id":"PMC_28492560","title":"miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28492560","citation_count":59,"is_preprint":false},{"pmid":"21347625","id":"PMC_21347625","title":"Time-dependent effects of Prkce deletion on glucose homeostasis and hepatic lipid metabolism on dietary lipid oversupply in mice.","date":"2011","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/21347625","citation_count":50,"is_preprint":false},{"pmid":"23457043","id":"PMC_23457043","title":"MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.","date":"2013","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23457043","citation_count":41,"is_preprint":false},{"pmid":"25950488","id":"PMC_25950488","title":"IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25950488","citation_count":40,"is_preprint":false},{"pmid":"18945988","id":"PMC_18945988","title":"Fetal exposure to cocaine causes programming of Prkce gene repression in the left ventricle of adult rat offspring.","date":"2008","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/18945988","citation_count":32,"is_preprint":false},{"pmid":"27312950","id":"PMC_27312950","title":"PRKCE gene encoding protein kinase C-epsilon-Dual roles at sarcomeres and mitochondria in cardiomyocytes.","date":"2016","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/27312950","citation_count":25,"is_preprint":false},{"pmid":"32869841","id":"PMC_32869841","title":"Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32869841","citation_count":24,"is_preprint":false},{"pmid":"28934384","id":"PMC_28934384","title":"SHORT syndrome due to a novel de novo mutation in PRKCE (Protein Kinase Cɛ) impairing TORC2-dependent AKT activation.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28934384","citation_count":18,"is_preprint":false},{"pmid":"35137073","id":"PMC_35137073","title":"Influence of PRKCE non-synonymous variants on protein dynamics and functionality.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35137073","citation_count":16,"is_preprint":false},{"pmid":"31191837","id":"PMC_31191837","title":"ANXA2, PRKCE, and OXT are critical differentially genes in Nonalcoholic fatty liver disease.","date":"2019","source":"Gastroenterology and hepatology from bed to bench","url":"https://pubmed.ncbi.nlm.nih.gov/31191837","citation_count":13,"is_preprint":false},{"pmid":"34108094","id":"PMC_34108094","title":"Genome-wide DNA methylation profiling in nonalcoholic fatty liver reveals predictive aberrant methylation in PRKCE and SEC14L3 promoters.","date":"2021","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/34108094","citation_count":11,"is_preprint":false},{"pmid":"36299231","id":"PMC_36299231","title":"PRKCE non-coding variants influence on transcription as well as translation of its gene.","date":"2022","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/36299231","citation_count":9,"is_preprint":false},{"pmid":"35985686","id":"PMC_35985686","title":"A Novel Cryptic t(2;3)(p21;q25) Translocation Fuses the WWTR1 and PRKCE Genes in Uterine Leiomyoma With 3q- as the Sole Visible Chromosome Abnormality.","date":"2022","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/35985686","citation_count":5,"is_preprint":false},{"pmid":"35800456","id":"PMC_35800456","title":"Variants in PRKCE and KLC1, Potential Regulators of Type I Psoriasis.","date":"2022","source":"Clinical, cosmetic and investigational dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35800456","citation_count":4,"is_preprint":false},{"pmid":"35582855","id":"PMC_35582855","title":"Maternal Prkce expression in mature oocytes is critical for the first cleavage facilitating maternal-to-zygotic transition in mouse early embryos.","date":"2022","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/35582855","citation_count":1,"is_preprint":false},{"pmid":"40914752","id":"PMC_40914752","title":"Deletion of the SHORT Syndrome Gene Prkce Results in Brain Atrophy and Cognitive and Motor Behavior Deficits in Mice.","date":"2025","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/40914752","citation_count":0,"is_preprint":false},{"pmid":"41123786","id":"PMC_41123786","title":"Characterization of a PRKCE::ETV6 fusion as a potential oncogenic driver in T-cell acute lymphoblastic leukemia.","date":"2025","source":"Molecular and cellular pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/41123786","citation_count":0,"is_preprint":false},{"pmid":"41883368","id":"PMC_41883368","title":"Cigarette Smoking-Regulated PRKCE Is Involved in Bladder Cancer Susceptibility through cGMP/PKG-Dependent Glycolysis.","date":"2025","source":"Environment & health (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/41883368","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.05.658128","title":"Mammalian epigenomic conservation of promoters and enhancers in the heart associates with trait-associated variation and impacts cardiomyocyte phenotypes","date":"2025-06-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.05.658128","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.22.629968","title":"Cortical projection neurons with distinct axonal connectivity employ ribosomal complexes with distinct protein compositions","date":"2024-12-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.22.629968","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.09.627650","title":"Identification of Myeloid Protein Kinase C – Epsilon as a Novel Atheroprotective Gene","date":"2024-12-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.09.627650","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.21.634055","title":"Modeling Synaptic Maturation from Growth Cone to Synapse in Human Organoids","date":"2025-01-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.21.634055","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14238,"output_tokens":3622,"usd":0.048522,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11417,"output_tokens":4156,"usd":0.080492,"stage2_stop_reason":"end_turn"},"total_usd":0.129014,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"A de novo partial loss-of-function mutation in PRKCE (PKCε) causes SHORT syndrome by impairing mTORC2-dependent AKT activation. The mutant PKCε bound to the mTORC2 component SIN1 with higher affinity than wild-type, altered mTORC2-dependent priming dynamics, and caused impaired mTORC2-dependent pAKT-S473 following rapamycin treatment, as well as reduced pFOXO1-S256 and pS6-S240/244 in patient lymphoblasts. Interaction with PDK1 and SIN1 was preserved in the mutant.\",\n      \"method\": \"Whole exome sequencing, kinase activity assay, phospho-specific antibody immunoblotting in patient lymphoblasts and HEK293 ectopic expression, co-immunoprecipitation of PDK1/SIN1 interactions\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction studies, kinase assay, phospho-readouts with multiple substrates, patient + cell-line models in a single focused study\",\n      \"pmids\": [\"28934384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRKCE is a direct target of miR-218-5p: miR-218-5p overexpression repressed luciferase activity of reporter constructs containing the 3'-UTR of PRKCE and reduced PRKCE protein expression. PRKCE promotes gemcitabine resistance in gallbladder cancer cells through upregulation of MDR1/P-glycoprotein.\",\n      \"method\": \"Luciferase 3'-UTR reporter assay, miRNA overexpression/knockdown, Western blotting, cell viability assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'-UTR reporter assay plus functional rescue experiments in cells, single lab\",\n      \"pmids\": [\"28492560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"miR-146a directly binds the 3'-UTR of PRKCE (confirmed by luciferase reporter assay) and decreases PKCε protein levels in papillary thyroid carcinoma cells, leading to increased apoptosis and suppressed tumor growth in a subcutaneous xenograft model. PKCε acts downstream of the Ras/Raf-1 pathway and inhibits mitochondrial apoptosis in thyroid cancer cells.\",\n      \"method\": \"Luciferase 3'-UTR reporter assay, miR-146a stable overexpression, Western blotting, apoptosis assays, xenograft tumor growth\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'-UTR reporter plus in vivo rescue, single lab\",\n      \"pmids\": [\"23457043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-205-5p directly targets PRKCE (validated by luciferase reporter assay) and negatively regulates its expression in gallbladder cancer stem cells. Overexpression of miR-205-5p or silencing of PRKCE inhibited drug resistance, proliferation, and colony formation while promoting apoptosis, and attenuated gemcitabine resistance in vivo.\",\n      \"method\": \"Luciferase 3'-UTR reporter assay, miRNA overexpression, PRKCE knockdown, apoptosis assays (Bax, Bcl-2, cleaved caspase 3 Western blot), mouse xenograft model\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'-UTR reporter plus in vivo xenograft, single lab\",\n      \"pmids\": [\"32869841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Deletion of Prkce in mice protects against diet-induced glucose intolerance via two temporally distinct mechanisms: (1) early protection via altered hepatic lipid partitioning that reduces fatty acid catabolism-derived reactive oxygen species (ROS), and (2) later enhancement of glucose-stimulated insulin secretion. Prkce-/- hepatocytes showed reduced ROS production in the presence of palmitate and altered mitochondrial oxidative capacity.\",\n      \"method\": \"Prkce knockout mice on high-fat diet, glucose tolerance tests, indirect calorimetry, iTRAQ quantitative proteomics, immunoblotting, primary hepatocyte assays, mitochondrial oxidative capacity measurements\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout model with multiple orthogonal phenotypic readouts (metabolic, proteomic, cellular) across time points\",\n      \"pmids\": [\"21347625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Fetal cocaine exposure programs cardiac Prkce gene repression in adult male rat offspring via DNA methylation of two Sp1 binding sites (-346 and -268) in the Prkce promoter. Methylation of these sites decreased SP1 binding affinity to the promoter, and reporter gene assays confirmed both Sp1 sites have a strong stimulatory role in Prkce gene activity. The effect was sex-dependent (males but not females showed decreased Prkce mRNA and both Sp1 sites methylated).\",\n      \"method\": \"Bisulfite sequencing/methylation analysis of Prkce promoter CpGs, luciferase reporter gene assay, electrophoretic mobility shift/SP1 binding assays, RT-PCR, in vivo rat model\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (methylation mapping, reporter assay, binding assay) in a single focused mechanistic study\",\n      \"pmids\": [\"18945988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Maternal Prkce transcript in mature oocytes is critical for the first cleavage and facilitating the maternal-to-zygotic transition in mice. Prkce knockout mice showed a significantly reduced 2-cell rate (32.4% vs 80.1% in wild-type) that was rescued by Prkce cRNA injection (76.7% 2-cell rate). Global transcriptional analysis of knockout embryos revealed 143 differentially expressed genes largely enriched in cell cycle regulation pathways.\",\n      \"method\": \"Prkce knockout mice, in vitro fertilization, cRNA rescue injection, microarray/RNA sequencing, RT-qPCR, Western blotting, immunofluorescence\",\n      \"journal\": \"Cell proliferation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with rescue experiment, multiple orthogonal methods in a single focused study\",\n      \"pmids\": [\"35582855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IPS-1-mediated anticancer signaling via IRF3 and IRF7 downregulates PRKCE (along with BCL2 and BIRC3) as part of its anti-apoptotic gene suppression program. Stable knockdown of IPS-1, IRF3, or IRF7 in IFN-non-responsive cancer cells reduced anticancer activity and suppressed downregulation of PRKCE.\",\n      \"method\": \"IPS-1 ectopic expression, stable shRNA knockdown of IPS-1/IRF3/IRF7, gene expression analysis, apoptosis assays in cancer cell lines\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via knockdown of pathway components with transcriptional and apoptotic readouts, single lab\",\n      \"pmids\": [\"25950488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PKCε deficiency in the central nervous system leads to cerebral and cerebellar atrophy and motor/social deficits. Mechanistically, deletion of PKCε results in downregulation of VEGF/PI3K-induced AKT activation, causing abnormal brain development. This is consistent with the SHORT syndrome phenotype previously linked to PRKCE mutation.\",\n      \"method\": \"Prkce knockout mice (CNS-specific), brain morphometry, behavioral testing, phospho-specific immunoblotting of AKT pathway components\",\n      \"journal\": \"Neuroscience bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean knockout with pathway readout, single lab, single paper\",\n      \"pmids\": [\"40914752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A PRKCE::ETV6 fusion gene resulting from a complex chromosomal rearrangement of chromosomes 2 and 12 in near-ETP T-ALL confers interleukin-independent proliferation and enhanced survival in cytokine-dependent cellular models (Ba/F3 pro-B cells and D1 T-cells), supporting its role as an oncogenic driver.\",\n      \"method\": \"Targeted genomic capture high-throughput sequencing, RNA sequencing, RT-PCR, Sanger sequencing, FISH, ectopic expression of PRKCE::ETV6 fusion in Ba/F3 and D1 cell lines, IL-independent proliferation and survival assays\",\n      \"journal\": \"Molecular and cellular pediatrics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell-based assay with two independent cell line models demonstrating transforming potential, single lab\",\n      \"pmids\": [\"41123786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In bladder cancer cells, decreased PRKCE expression (associated with the rs4953292 A allele combined with 4-aminobiphenyl treatment) upregulates PKG and promotes phosphorylation of VASP within the cGMP-PKG signaling pathway, enhancing glucose uptake, lactate generation, and extracellular acidification rate to reprogram glycolysis, thereby promoting bladder cancer susceptibility.\",\n      \"method\": \"Functional experiments in 4-ABP-treated bladder cancer cells, allele-specific PRKCE expression analysis, ECAR measurement, lactate/glucose uptake assays, phospho-VASP immunoblotting\",\n      \"journal\": \"Environment & health\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional cell-based mechanistic assays with pathway readouts, single lab, single paper\",\n      \"pmids\": [\"41883368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRKCE protein associates with ribosomal complexes specifically in subcerebral projection neurons (SCPN) but not callosal projection neurons (CPN) during axonal connectivity establishment in mouse cortex. This SCPN-specific ribosome association was validated by ribosome immunoprecipitation and PKCε has enriched gene expression in SCPN, suggesting a role in subtype-specific translational regulation during circuit formation.\",\n      \"method\": \"Retrograde neuronal labeling, FACS purification of neuron subtypes, ribosome immunoprecipitation, ultra-low-input mass spectrometry, gene expression analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ribosome pulldown in sorted neurons, preprint, single lab, functional consequence not yet experimentally established\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Myeloid PKCε restricts lipid uptake in macrophages by a mechanism independent of scavenger receptor expression. PKCε-deficient macrophages (mεKO) retained significantly more cholesterol and lipid droplets upon lipid loading in vitro and in vivo, and RNA sequencing implicated higher expression of genes related to endocytosis in mεKO macrophages. mεKO mice developed larger atherosclerotic plaques with more necrosis and thinner collagen caps.\",\n      \"method\": \"Myeloid-specific Prkce knockout mice (LysM Cre PKCε fl/fl), bone marrow-derived macrophage lipid loading assays, cholesterol retention assays, RNA sequencing, in vivo hypercholesterolemia model, plaque histomorphometry\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean conditional knockout with in vitro and in vivo phenotypic readouts and RNA sequencing pathway analysis, preprint\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"PKCε (PRKCE) is a serine/threonine kinase that operates at the intersection of multiple signaling pathways: it facilitates mTORC2-dependent AKT activation (loss-of-function mutations cause SHORT syndrome), promotes MDR1/P-gp-mediated drug resistance in cancer, modulates hepatic lipid partitioning and mitochondrial ROS production to influence glucose homeostasis, drives Prkce promoter activity via Sp1 binding sites (subject to epigenetic repression by DNA methylation), is required for the first embryonic cleavage by supporting cell cycle regulation during maternal-to-zygotic transition, restricts macrophage lipid uptake independently of scavenger receptor expression, and regulates glycolytic reprogramming through the cGMP-PKG pathway; its activity is spatiotemporally controlled by subcellular targeting to sarcomeres, mitochondria, and ribosomal complexes in a cell-type-specific manner.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PRKCE encodes PKCε, a serine/threonine kinase that integrates growth-factor, metabolic, and stress signaling to regulate cell survival, lipid handling, and development [#0, #4]. In the mTORC2 module, PKCε engages the mTORC2 component SIN1 to support mTORC2-dependent priming and AKT-S473 phosphorylation; a de novo partial loss-of-function mutation that binds SIN1 with higher affinity and impairs downstream pAKT-S473, pFOXO1-S256, and pS6 phosphorylation causes SHORT syndrome [#0], and CNS-restricted loss likewise downregulates VEGF/PI3K-driven AKT activation, producing cerebral and cerebellar atrophy with motor and social deficits [#8]. Metabolically, PKCε shapes hepatic lipid partitioning and mitochondrial oxidative capacity, with its deletion reducing fatty-acid-derived ROS and protecting against diet-induced glucose intolerance [#4], and in macrophages it restricts cholesterol and lipid-droplet accumulation independently of scavenger-receptor expression, limiting atherosclerotic plaque burden [#12]. In cancer, PKCε is anti-apoptotic: it acts downstream of Ras/Raf-1 to inhibit mitochondrial apoptosis [#2] and drives MDR1/P-glycoprotein-mediated gemcitabine resistance [#1], and it is held in check by multiple microRNAs (miR-218-5p, miR-146a, miR-205-5p) that bind its 3'-UTR [#1, #2, #3]. PKCε is also required for the first embryonic cleavage and the maternal-to-zygotic transition through cell-cycle gene regulation [#6], and its own promoter is controlled by Sp1-binding sites subject to DNA-methylation-dependent repression [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established how PRKCE expression itself is transcriptionally controlled, showing the gene is a methylation-sensitive Sp1 target and a node for epigenetic programming.\",\n      \"evidence\": \"Bisulfite methylation mapping, luciferase reporter and SP1 binding assays in a fetal-cocaine-exposure rat model\",\n      \"pmids\": [\"18945988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sex-specific basis of the methylation effect not mechanistically explained\", \"Does not address PKCε protein function, only its transcriptional regulation\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a metabolic role for PKCε, resolving that its deletion protects against glucose intolerance via hepatic lipid partitioning/ROS and enhanced insulin secretion.\",\n      \"evidence\": \"Prkce knockout mice on high-fat diet with glucose tolerance tests, proteomics, and primary hepatocyte mitochondrial assays\",\n      \"pmids\": [\"21347625\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase substrates linking PKCε to lipid partitioning not identified\", \"Tissue source of the insulin-secretion benefit not pinpointed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed PKCε is an anti-apoptotic effector downstream of Ras/Raf-1 and a direct microRNA target, framing it as a tumor-promoting kinase.\",\n      \"evidence\": \"miR-146a 3'-UTR luciferase reporter, overexpression, apoptosis assays and xenografts in papillary thyroid carcinoma\",\n      \"pmids\": [\"23457043\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrates mediating mitochondrial apoptosis inhibition not defined\", \"Single tumor type\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed PRKCE within an innate-immune anti-cancer program, identifying it as a gene suppressed by IPS-1/IRF3/IRF7 signaling.\",\n      \"evidence\": \"IPS-1 expression and shRNA knockdown of IPS-1/IRF3/IRF7 with transcriptional and apoptosis readouts in cancer cells\",\n      \"pmids\": [\"25950488\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PRKCE downregulation is causal for the apoptotic effect or correlative not resolved\", \"Direct transcriptional control of PRKCE by IRFs not demonstrated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected PKCε to drug resistance, showing miR-218-5p represses PRKCE and that PKCε drives MDR1/P-glycoprotein-mediated gemcitabine resistance.\",\n      \"evidence\": \"3'-UTR luciferase reporter, miRNA modulation, and viability assays in gallbladder cancer cells\",\n      \"pmids\": [\"28492560\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking PKCε activity to MDR1 upregulation not defined\", \"No in vivo resistance model in this study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined PKCε's role in the mTORC2-AKT axis and established its first Mendelian disease link, showing a SIN1-binding partial loss-of-function mutation causes SHORT syndrome.\",\n      \"evidence\": \"Whole exome sequencing, kinase assays, co-IP of PDK1/SIN1, and phospho-readouts in patient lymphoblasts and HEK293 cells\",\n      \"pmids\": [\"28934384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of enhanced SIN1 binding by the mutant not solved\", \"How altered priming translates to multi-substrate AKT-pathway impairment incompletely mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reinforced the microRNA-PKCε resistance axis in cancer stem cells, validating miR-205-5p as a further direct repressor of PRKCE.\",\n      \"evidence\": \"3'-UTR luciferase reporter, miRNA overexpression, PRKCE knockdown, and xenografts in gallbladder cancer stem cells\",\n      \"pmids\": [\"32869841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overlap/redundancy among the multiple PRKCE-targeting miRNAs not addressed\", \"Downstream effectors of PKCε in stemness not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a developmental requirement for maternal PKCε, showing it is essential for the first embryonic cleavage and maternal-to-zygotic transition through cell-cycle gene regulation.\",\n      \"evidence\": \"Prkce knockout mice with cRNA rescue, IVF, transcriptomics, and immunofluorescence\",\n      \"pmids\": [\"35582855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase targets controlling the cleavage cell cycle not identified\", \"Mechanism connecting PKCε to the 143 differentially expressed cell-cycle genes unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended the mTORC2/AKT role to brain development, showing CNS PKCε loss downregulates VEGF/PI3K-AKT signaling and causes atrophy, consistent with SHORT syndrome.\",\n      \"evidence\": \"CNS-specific Prkce knockout mice with morphometry, behavior, and AKT-pathway immunoblotting\",\n      \"pmids\": [\"40914752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single paper\", \"Cell-autonomous versus vascular contribution to atrophy not separated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Implicated PRKCE in oncogenic gene fusion, showing a PRKCE::ETV6 fusion confers cytokine-independent proliferation in T-ALL models.\",\n      \"evidence\": \"Genomic/RNA sequencing, FISH, and ectopic fusion expression with IL-independent proliferation/survival assays in Ba/F3 and D1 cells\",\n      \"pmids\": [\"41123786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling output of the fusion protein not delineated\", \"Patient-level oncogenicity beyond cell-line models not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked reduced PRKCE to glycolytic reprogramming, showing low PKCε upregulates PKG/phospho-VASP via cGMP-PKG to enhance glycolysis and bladder cancer susceptibility.\",\n      \"evidence\": \"Allele-specific expression and functional ECAR/lactate/glucose-uptake and phospho-VASP assays in 4-ABP-treated bladder cancer cells\",\n      \"pmids\": [\"41883368\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single paper\", \"Direct mechanism by which PKCε loss derepresses PKG not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified a myeloid lipid-handling function, showing PKCε restricts macrophage cholesterol/lipid-droplet accumulation independently of scavenger receptors and limits atherosclerosis.\",\n      \"evidence\": \"Myeloid-specific Prkce knockout mice with macrophage lipid-loading, RNA-seq, and plaque histomorphometry (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endocytic genes implicated but causal substrate not identified\", \"Preprint, not peer-reviewed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Suggested a subtype-specific translational role, finding PKCε associates with ribosomes selectively in subcerebral projection neurons during circuit formation.\",\n      \"evidence\": \"Ribosome immunoprecipitation and mass spectrometry in FACS-purified mouse cortical neuron subtypes (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Functional consequence of ribosome association not experimentally established\", \"Preprint, single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct phosphorylation substrates that mediate PKCε's effects across mTORC2 signaling, lipid metabolism, cell-cycle control, and drug resistance remain largely unidentified.\",\n      \"evidence\": \"No discovery in the corpus maps PKCε kinase activity to specific phosphorylated targets in these processes\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No defined substrate set\", \"Spatiotemporal targeting mechanisms to sarcomeres/mitochondria/ribosomes not mechanistically resolved\", \"Unified model linking diverse phenotypes to kinase activity absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005840\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 8, 10]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 12]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 7]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"complexes\": [\"mTORC2\"],\n    \"partners\": [\"SIN1\", \"PDK1\", \"SP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}